AxisPharm

Executive Summary

AxisPharm is a San Diego-based contract research and development organization (CRO/CDMO) founded in 2017 that specializes in bioconjugation services, offering a comprehensive suite of linkers—including PEG, peptide, and ADC linkers—and full-spectrum mass spectrometry-based analytical support for proteomics, metabolomics, and PK/PD bioanalysis. As a leading supplier of target-specific probes and bioconjugation solutions, the company serves biotech and pharmaceutical clients globally, supporting drug development from discovery through manufacturing. Despite being a private company with limited publicly available financial data, AxisPharm has established a niche in the growing ADC and bioconjugation market, leveraging its technical expertise in linker chemistry and analytical services to drive client engagements.

Upcoming Catalysts (preview)

• Q3 2026Launch of novel ADC linker platform with enhanced stability and payload release profiles70% success
• Q4 2026Strategic partnership with a top-20 pharma for integrated bioconjugation and analytical services50% success
• Q1 2027Expansion of mass spectrometry capabilities into new therapeutic modalities (e.g., PROTACs, oligonucleotides)60% success